Halitosis, commonly known as bad breath, is a condition that can significantly impact social interactions and quality of life, particularly in children. This distressing issue is often exacerbated by mouth breathing, a habit in many youngsters that compromises the natural antibacterial properties
Recent research conducted by the University of Cologne and the Centre for Genomic Regulation (CRG) in Barcelona has led to a groundbreaking discovery in cancer research. Published in the journal eLIFE, the study overturns the long-standing belief that tumors grow predominantly at their outer edges.
In a significant development for cardiovascular medicine, BridgeBio's Attruby (acoramidis) has received FDA approval for treating Transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, marking a crucial milestone for a rare and severe heart condition that can lead to fatal outcomes if left
In a bold move to tackle one of the most formidable cancers, Anocca AB has announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for their innovative VIDAR-1 Phase I/II multi-asset trial, targeting advanced pancreatic cancer. The pioneering trial, set
The digital health startup ecosystem has experienced a dramatic transformation from 2021 to 2024. Once buoyed by a record-breaking influx of venture capital, the landscape now appears stark and challenging for many startups. The rush of investments in 2021 brought about hopeful optimism, but the
The recent study by the research group at LMU University Hospital delves into enhancing the reliability of diagnosing Alzheimer's disease. This effort is in response to the upcoming authorization in Germany of the first drugs aimed at decelerating the progression of Alzheimer's disease, notably
Freya Biosciences, a transatlantic biotech company specializing in women's health, has successfully secured a substantial $10.4 million investment from the Bill & Melinda Gates Foundation, along with an additional $1.4 million in financing from the Export and Investment Fund of Denmark. This
Artificial Intelligence, particularly AI-based software like AlphaFold2, is transforming the field of protein design by enabling precise customization of proteins for therapeutic, diagnostic, and chemical applications. The advent of AI in this realm offers groundbreaking possibilities, particularly
Rare diseases, though individually uncommon, collectively impact millions of people worldwide. Most of these conditions manifest in childhood, with genetic factors being the primary cause in about 80% of cases. Children with rare genetic disorders often endure prolonged diagnostic journeys
The pharmaceutical industry stands on the precipice of a monumental shift, driven by the rapid progress in artificial intelligence (AI). By 2025, AI is expected to significantly transform drug development processes, making them more efficient, accurate, and personalized. This article delves into
